Reinforcing its central nervous system interests, Lundbeck has signed a definitive agreement to acquire Prexton Therapeutics, a biotech that is focused on the development of novel compounds for neurodegenerative disorders. The deal is worth up to EUR905 M (US$1.1 B), including an upfront payment of EUR100 M (US$123 M). Lundbeck will gain a pipeline of metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs) that target the non-dopaminergic route of treatment in Parkinson’s disease. The most advanced asset is the Phase II candidate, foliglurax, which is first in its class to enter clinical development.